Approval · Notice of Compliance 19752 · 2017
SUBOXONE: Notice of Compliance 19752
Issued September 1, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19752
- Date
- September 1, 2017
- Company
- Indivior Uk LimitedHull, --, United Kingdom
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of new tablet strengths
Products in this notice
Medicinal ingredients
- BUPRENORPHINE HYDROCHLORIDE 12 MG per TAB
- NALOXONE HYDROCHLORIDE DIHYDRATE 3 MG per TAB
- BUPRENORPHINE HYDROCHLORIDE 16 MG per TAB
- NALOXONE HYDROCHLORIDE DIHYDRATE 4 MG per TAB